Centre Hospitalier Universitaire de Sherbrooke

Running trials

• Recruiting

  Improving Access to Pelvic Health Physiotherapy for Endometriosis

  NCT07731776· Université de Sherbrooke· Source

• Recruiting

  Thyroid Artery Embolization for the Treatment of Compressive Goiters.

  NCT07360587· Centre de recherche du Centre hospitalier universitaire de Sherbrooke· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Intravascular Ultrasound for Peripheral Artery Disease Revascularization

  NCT06979284· Hamilton Health Sciences Corporation· Source

• Recruiting

  Taurine Supplementation in Long COVID

  NCT06721949· Phase 2/3· University of Alberta· Source

• Recruiting

  Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

  NCT07175428· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

  NCT06942039· Early phase 1· C17 Council· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Effect of Hi-OxSR for the Treatment of Post COVID Condition

  NCT06928506· University Health Network, Toronto· Source

• Not yet recruiting

  Brain Low-risk Aneurysm Stereotactic Radiosurgical Trial

  NCT06047951· Dr David Mathieu· Source

• Recruiting

  Transdiagnostic Internet Cognitive-behavior Therapy for Mixed Anxiety and Depressive Symptoms in Postnatal Women

  NCT06778096· Université de Sherbrooke· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Not yet recruiting

  Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

  NCT06855589· Phase 3· Charles LeMoyne Hospital· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  Deep Brain Stimulation for Refractory Trigeminal Neuralgia with a Pontine Lesion

  NCT05451251· Phase 1· Université de Sherbrooke· Source

• Active, not recruiting

  Support-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care

  NCT05910840· Anne-Sophie Brazeau· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Ivy Brain Tumor Center· Source

• Recruiting

  First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT06217822· Phase 1· Bayer· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

• Active, not recruiting

  A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

  NCT05794906· Phase 3· Bayer· Source

• Active, not recruiting

  HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)

  NCT05636995· Université de Sherbrooke· Source

• Active, not recruiting

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· Phase 3· European Myeloma Network B.V.· Source

• Recruiting

  Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study

  NCT04973397· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Recruiting

  Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

  NCT05255653· Phase 3· Leiden University Medical Center· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

  NCT04658862· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

  NCT04136353· Phase 3· University of Sydney· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Active, not recruiting

  Benzodiazepine-free Cardiac Anesthesia for Reduction of Postoperative Delirium

  NCT03928236· Population Health Research Institute· Source

• Active, not recruiting

  Fit-for-Fertility Multicenter Randomized Controlled Trial

  NCT03908099· Université de Sherbrooke· Source

• Recruiting

  Registry of Patients Living With Type 1 Diabetes

  NCT03720197· Institut de Recherches Cliniques de Montreal· Source

• Active, not recruiting

  9-ING-41 in Patients With Advanced Cancers

  NCT03678883· Phase 2· Actuate Therapeutics Inc.· Source

• Active, not recruiting

  International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

  NCT03386734· Centre Hospitalier Universitaire de Besancon· Source

• Recruiting

  Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach With a New LBBB After TAVI

  NCT03303612· Montreal Heart Institute· Source

• Active, not recruiting

  Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

  NCT03057106· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  TDM Guided Early Optimization of ADAL in Crohn's Disease

  NCT03261102· waqqas.afif· Source

• Active, not recruiting

  Augmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence

  NCT02150902· Ottawa Heart Institute Research Corporation· Source

• Active, not recruiting

  Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

  NCT01924819· Phase 2/3· Australasian Gastro-Intestinal Trials Group· Source

• Recruiting

  Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset

  NCT00512239· Gilles Boire· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation2 recruiting
• Chronic kidney disease2 recruiting
• Long COVID and ME/CFS2 recruiting
• Prostate cancer2 recruiting
• Stroke2 recruiting
• Aortic stenosis1 recruiting
• Brain aneurysm1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Endometriosis1 recruiting
• Follicular lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Multiple sclerosis1 recruiting
• Neuroblastoma1 recruiting
• Peripheral artery disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Trigeminal neuralgia1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  Alleviating Dyspnea With Non-Invasive Neuromodulation

  NCT06985628· Université de Sherbrooke· Source

• Completed

  Obesity-fertility Cohort Study: Protocol for the Assessment of Children Aged 6-12 Years and Their Mothers

  NCT06402825· Université de Sherbrooke· Source

• Completed

  Acute Oral Ketones or Carbohydrate Supplement Modify Heart Function in Heart Failure?

  NCT05651529· Université de Sherbrooke· Source

• Completed

  An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

  NCT04564079· Exactis Innovation· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Completed

  I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

  NCT03939689· Phase 2· Progenics Pharmaceuticals, Inc.· Source

• Completed

  Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE

  NCT03488420· Montreal Heart Institute· Source

• Completed

  Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

  NCT02978404· Phase 2· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Completed

  Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

  NCT02973789· Phase 3· NovoCure GmbH· Source

• Completed

  Antiarrhythmics or Ablation for Ventricular Tachycardia 2

  NCT02830360· Phase 4· John Sapp· Source

• Completed

  Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

  NCT02831959· Phase 3· NovoCure GmbH· Source

• Completed

  Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

  NCT02630693· Phase 2· Canadian Cancer Trials Group· Source

• Completed

  Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

  NCT02168829· Phase 4· Ottawa Heart Institute Research Corporation· Source

• Completed

  Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation

  NCT01994252· Ottawa Heart Institute Research Corporation· Source

• Completed

  Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  NCT00673842· Phase 3· University of Calgary· Source